David A. Siegel Emergent Bio Solutions Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Emergent Bio Solutions Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 43,200 shares of EBS stock, worth $436,752. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,200

Previous 283,700 84.77%

Holding current value

$436,752

Previous $1.81 Million 78.95%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$5.63 - $9.32 $1.35 Million - $2.24 Million	-240,500 Reduced 84.77%	43,200 $381,000
Q2 2025 Aug 14, 2025	SELL	$4.26 - $6.94 $549,540 - $895,260	-129,000 Reduced 31.26%	283,700 $1.81 Million
Q1 2025 May 15, 2025	SELL	$4.66 - $11.66 $1.14 Million - $2.84 Million	-243,800 Reduced 37.14%	412,700 $2.01 Million
Q4 2024 Feb 14, 2025	BUY	$7.72 - $11.97 $625,320 - $969,570	81,000 Added 14.07%	656,500 $6.28 Million
Q3 2024 Nov 14, 2024	BUY	$5.72 - $14.77 $572 - $1,477	100 Added 0.02%	575,500 $4.81 Million

Q2 2024 Aug 14, 2024	SELL	$1.86 - $6.98 $927,024 - $3.48 Million	-498,400 Reduced 46.41%	575,400 $3.92 Million
Q1 2024 May 15, 2024	SELL	$1.5 - $3.41 $20,850 - $47,399	-13,900 Reduced 1.28%	1,073,800 $2.72 Million
Q4 2023 Feb 14, 2024	BUY	$1.82 - $3.16 $37,128 - $64,464	20,400 Added 1.91%	1,087,700 $2.61 Million
Q3 2023 Nov 14, 2023	BUY	$3.17 - $7.91 $1.11 Million - $2.77 Million	350,400 Added 48.88%	1,067,300 $3.63 Million
Q2 2023 Aug 14, 2023	BUY	$7.35 - $13.21 $1.67 Million - $3.01 Million	227,800 Added 46.58%	716,900 $5.27 Million
Q1 2023 May 15, 2023	BUY	$7.79 - $16.29 $2 Million - $4.17 Million	256,200 Added 110.0%	489,100 $5.07 Million
Q4 2022 Feb 14, 2023	SELL	$11.0 - $21.45 $40,700 - $79,365	-3,700 Reduced 1.56%	232,900 $2.75 Million
Q3 2022 Nov 14, 2022	SELL	$20.09 - $35.8 $126,567 - $225,539	-6,300 Reduced 2.59%	236,600 $4.97 Million
Q2 2022 Aug 15, 2022	SELL	$27.42 - $43.63 $660,822 - $1.05 Million	-24,100 Reduced 9.03%	242,900 $7.54 Million
Q1 2022 May 16, 2022	BUY	$36.48 - $52.22 $4.49 Million - $6.43 Million	123,200 Added 85.67%	267,000 $11 Million
Q4 2021 Feb 14, 2022	BUY	$33.11 - $55.01 $4.58 Million - $7.61 Million	138,400 Added 2562.96%	143,800 $6.25 Million
Q3 2021 Nov 15, 2021	SELL	$50.07 - $66.05 $12.4 Million - $16.4 Million	-248,600 Reduced 97.87%	5,400 $270,000
Q2 2021 Aug 16, 2021	BUY	$56.61 - $80.46 $14.4 Million - $20.4 Million	254,000 New	254,000 $16 Million
Q4 2020 Feb 16, 2021	SELL	$79.17 - $111.47 $12.2 Million - $17.1 Million	-153,700 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$81.91 - $134.94 $12.6 Million - $20.7 Million	153,700 New	153,700 $15.9 Million
Q3 2019 Nov 14, 2019	SELL	$40.6 - $57.2 $263,900 - $371,800	-6,500 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$39.92 - $53.86 $259,480 - $350,090	6,500 New	6,500 $314,000
Q1 2019 May 15, 2019	SELL	$48.23 - $66.16 $303,849 - $416,808	-6,300 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$55.63 - $73.24 $572,989 - $754,372	-10,300 Reduced 62.05%	6,300 $373,000
Q3 2018 Nov 14, 2018	SELL	$52.05 - $66.51 $1.38 Million - $1.77 Million	-26,590 Reduced 61.57%	16,600 $1.09 Million
Q2 2018 Aug 14, 2018	SELL	$48.33 - $55.64 $546,129 - $628,732	-11,300 Reduced 20.74%	43,190 $2.18 Million
Q1 2018 May 15, 2018	SELL	$44.44 - $54.39 $444,400 - $543,900	-10,000 Reduced 15.51%	54,490 $2.87 Million
Q4 2017 Feb 14, 2018	BUY	$37.77 - $47.75 $351,261 - $444,075	9,300 Added 16.85%	64,490 $3 Million
Q3 2017 Nov 14, 2017	BUY	$34.14 - $40.45 $1.88 Million - $2.23 Million	55,190	55,190 $2.23 Million

Others Institutions Holding EBS

# of Institutions

192

Shares Held

41.3M

Call Options Held

899K

Put Options Held

256K

View Full List

About Emergent BioSolutions Inc.

Ticker EBS
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,861,500
Market Cap $504M
Description
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emergi...

More about EBS

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account